Evidence map›Paper›PMID 15923109›Full record

ArticleCellular signalling2006

Inhibition of mixed-lineage kinase (MLK) activity during G2-phase disrupts microtubule formation and mitotic progression in HeLa cells.

Hyukjin Cha, Surabhi Dangi, Carolyn E Machamer, Paul Shapiro

Open access · greenAbstract read
In one paragraph

Article in Cellular signalling, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hyukjin ChaDepartment of Pharmaceutical Sciences, University of Maryland, School of Pharmacy Baltimore, Maryland, USA.
Surabhi Dangi
Carolyn E Machamer
Paul Shapiro
University of Maryland, Baltimore · USJohns Hopkins Medicine · US

Funding

Development of ERK docking domain inhibitorsR21CA105299 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHAPIRO, PAUL S · 2004 to 2005
$267k
NCI NIH HHS R21 CA105299
6 · The paper itself

Abstract

The mixed-lineage kinases (MLK) are serine/threonine protein kinases that regulate mitogen-activated protein (MAP) kinase signaling pathways in response to extracellular signals. Recent studies indicate that MLK activity may promote neuronal cell death through activation of the c-Jun NH2-terminal kinase (JNK) family of MAP kinases. Thus, inhibitors of MLK activity may be clinically useful for delaying the progression of neurodegenerative diseases, such as Parkinson's. In proliferating non-neuronal cells, MLK may have the opposite effect of promoting cell proliferation. In the current studies we examined the requirement for MLK proteins in regulating cell proliferation by examining MLK function during G2 and M-phase of the cell cycle. The MLK inhibitor CEP-11004 prevented HeLa cell proliferation by delaying mitotic progression. Closer examination revealed that HeLa cells treated with CEP-11004 during G2-phase entered mitosis similar to untreated G2-phase cells. However, CEP-11004 treated cells failed to properly exit mitosis and arrested in a pro-metaphase state. Partial reversal of the CEP-11004 induced mitotic arrest could be achieved by overexpression of exogenous MLK3. The effects of CEP-11004 treatment on mitotic events included the inhibition of histone H3 phosphorylation during prophase and prior to nuclear envelope breakdown and the formation of aberrant mitotic spindles. These data indicate that MLK3 might be a unique target to selectively inhibit transformed cell proliferation by disrupting mitotic spindle formation resulting in mitotic arrest.

Indexed as

AnimalsCarbazolesCell CycleCell DivisionCell LineCell ProliferationEnzyme InhibitorsG2 PhaseHeLa CellsHistonesHumansIndolesMAP Kinase Kinase KinasesMiceMicrotubulesMitogen-Activated Protein Kinase Kinase Kinase 11CarbazolesCEP-11004Enzyme InhibitorsHistonesIndolesMAP Kinase Kinase KinasesMitogen-Activated Protein Kinase Kinase Kinase 11Protein Serine-Threonine Kinases

Identifiers

PMID15923109
PMCPMC2835151
OpenAlexW2070347745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.